Starling Oncology, Inc. (DFPH) Return on equity 2020–2024
Starling Oncology, Inc. (DFPH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-1801.7%FY2024 · since FY2020: -51.0% → -1801.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -1801.7% | -1656.0 pp |
| FY2023 | -145.7% | -145.8 pp |
| FY2022 | 0.1% | +10.6 pp |
| FY2021 | -10.5% | +40.5 pp |
| FY2020 | -51.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice